One case of upper respiratory tract infection was reported in the LD-IL-2 group, whereas 5 patients ([16.7%]) had upper respiratory tract infections, 3 (10.0%) had urinary tract infections, and 1 (3.3%) had herpes zoster in the placebo group during the trial (eTable 2 in Supplement 2). This evidence concerns the gene IL2 and Recurrent upper respiratory tract infections.